Literature DB >> 9780223

Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis.

W S Begolka1, C L Vanderlugt, S M Rahbe, S D Miller.   

Abstract

Multiple sclerosis is an immune-mediated demyelinating disease of unknown etiology that presents with either a chronic-progressive or relapsing-remitting clinical course. Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) and relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) in the SJL/J mouse are both relevant murine CD4+ T cell-mediated demyelinating models that recapitulate the multiple sclerosis disease phenotypes. To determine the cellular and molecular basis for these observed differences in clinical course, we quantitatively analyzed the temporal expression of pro- and antiinflammatory cytokine mRNA expression in the central nervous system (CNS) and the phenotype of the inflammatory mononuclear infiltrates. TMEV-infected SJL/J mice expressed IFN-gamma, TNF-alpha, IL-10, and IL-4 mRNA during the preclinical phase, and their levels continued to increase throughout the duration of the chronic-progressive disease course. These data correlated with the continued presence of both CD4+ T cells and F4/80+ macrophages within the CNS infiltrates. In contrast, SJL/J mice with PLP(139-151)-induced R-EAE displayed a biphasic pattern of CNS expression for the proinflammatory cytokines, IFN-gamma and TNF-alpha, with expression peaking at the height of the acute phase and relapse(s). This pattern correlated with dynamic changes in the CD4+ T cell and F4/80+ macrophage populations during relapsing-remitting disease progression. Interestingly, IL-4 message was undetectable until disease remission(s), demonstrating its potential role in the intrinsic regulation of ongoing disease, whereas IL-10 was continuously expressed, arguing against a regulatory role in either disease. These data suggest that the kinetics of cytokine expression together with the nature of the persistent inflammatory infiltrates are major contributors to the differences in clinical course between TMEV-IDD and R-EAE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780223

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; C Benou; A D Salama; M J Grusby; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease.

Authors:  JoAnn P Palma; Daeho Kwon; Neil A Clipstone; Byung S Kim
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 4.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

5.  IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis.

Authors:  C C Walline; S Kanakasabai; J J Bright
Journal:  Genes Immun       Date:  2010-09-23       Impact factor: 2.676

Review 6.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

7.  Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  William J Karpus; Kevin J Kennedy; Brian T Fife; Jamie L Bennett; Mauro C Dal Canto; Steven L Kunkel; Nicholas W Lukacs
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

8.  Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection.

Authors:  Mary W Meagher; Robin R Johnson; Erin E Young; Elisabeth G Vichaya; Shannon Lunt; Elizabeth A Hardin; Marilyn A Connor; C Jane R Welsh
Journal:  Brain Behav Immun       Date:  2007-06-25       Impact factor: 7.217

Review 9.  Statins--treatment option for central nervous system autoimmune disease?

Authors:  Martin S Weber; Lawrence Steinman; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants.

Authors:  Antje Kroner; Nicholas Schwab; Chi Wang Ip; Sonja Ortler; Kerstin Göbel; Klaus-Armin Nave; Mathias Mäurer; Rudolf Martini; Heinz Wiendl
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.